Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
4.980
+0.080 (1.63%)
At close: Apr 1, 2026, 4:00 PM EDT
4.920
-0.060 (-1.20%)
After-hours: Apr 1, 2026, 6:38 PM EDT
Candel Therapeutics Employees
Candel Therapeutics had 55 employees as of December 31, 2025. The number of employees increased by 17 or 44.74% compared to the previous year.
Employees
55
Change (1Y)
17
Growth (1Y)
44.74%
Revenue / Employee
n/a
Profits / Employee
-$694,218
Market Cap
364.77M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 55 | 17 | 44.74% |
| Dec 31, 2024 | 38 | -4 | -9.52% |
| Dec 31, 2023 | 42 | -34 | -44.74% |
| Dec 31, 2022 | 76 | 11 | 16.92% |
| Dec 31, 2021 | 65 | 24 | 58.54% |
| Mar 31, 2021 | 50 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 650 |
| Ginkgo Bioworks Holdings | 485 |
| Invivyd | 122 |
| Enanta Pharmaceuticals | 120 |
| Niagen Bioscience | 117 |
| PureTech Health | 56 |
| DiaMedica Therapeutics | 28 |
| Benitec Biopharma | 19 |
CADL News
- 15 days ago - Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors - GlobeNewsWire
- 20 days ago - Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 23 days ago - Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting - GlobeNewsWire
- 4 weeks ago - Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston - GlobeNewsWire
- 5 weeks ago - Stock Market Today: Dow Jones, S&P 500 Futures Rise Ahead Of Q4 GDP Numbers—Grail, Candel Therapeutics, Copart In Focus - Benzinga
- 5 weeks ago - Candel Therapeutics Announces Pricing of Public Offering - GlobeNewsWire
- 5 weeks ago - Candel Therapeutics Announces Proposed $100 Million Public Offering - GlobeNewsWire